Acrivon Therapeutics (ACRV) is currently trading below its cash value, reflecting market skepticism despite promising early clinical data from its AP3 platform, which enables precision patient-matching for kinase inhibitor therapies. The company has shown a 50% response rate in serous endometrial cancer with its drug ACR-368. Key upcoming catalysts include Phase 2b data for ACR-368 and Phase 1 expansion results for ACR-2316, which are critical for reducing risk and expanding commercial potential. RA Capital's increased stake to 28% at $1.80 per share signals confidence amid challenges like high cash burn and patent issues.
Morgan Stanley increased its price target for United Airlines to $190, suggesting nearly 60% upside from the current price of $118.81. The airline's stock has surged 235% since October 2023, driven by a strong rebound in international travel and rais...
Citizens Financial Group reported a strong Q2 performance with earnings per share of $1.30, surpassing estimates by 4% and marking a 41% increase year-over-year. The bank also posted revenue of $2.28 billion, beating expectations and continuing a fou...
Yara International ASA is set to release its Q2 2026 earnings on July 17, with analysts expecting an EPS of $1.19 and revenue of $5.14 billion. The fertilizer industry faces challenges from rising raw material costs and potential demand decline due t...
Cycurion received a Nasdaq delisting notice due to its stock price falling below the $1 minimum for 31 consecutive days. The company is appealing the decision, which allows its shares to keep trading on Nasdaq during the review. Cycurion is focused o...
TDb Split Corp. plans a 15-for-100 share split for its Class A shares, effective for shareholders of record on July 24, 2026, pending TSX approval. Following the split, shareholders will receive the same $0.05 monthly cash distribution per share, eff...
